作者
Susan E Dorman, Samuel G Schumacher, David Alland, Pamela Nabeta, Derek T Armstrong, Bonnie King, Sandra L Hall, Soumitesh Chakravorty, Daniela M Cirillo, Nestani Tukvadze, Nino Bablishvili, Wendy Stevens, Lesley Scott, Camilla Rodrigues, Mubin I Kazi, Moses Joloba, Lydia Nakiyingi, Mark P Nicol, Yonas Ghebrekristos, Irene Anyango, Wilfred Murithi, Reynaldo Dietze, Renata Lyrio Peres, Alena Skrahina, Vera Auchynka, Kamal Kishore Chopra, Mahmud Hanif, Xin Liu, Xing Yuan, Catharina C Boehme, Jerrold J Ellner, Claudia M Denkinger, Yukari C Manabe, David Hom, Rusudan Aspindzelashvili, Anura David, Utkarsha Surve, Louis Henry Kamulegeya, Sheila Nabweyambo, Shireen Surtie, Nchimunya Hapeela, Kevin P Cain, Janet Agaya, Kimberly D McCarthy, Patricia Marques-Rodrigues, Luiz Guilherme Schmidt Castellani, Pedro Sousa Almeida, Paola Poloni Lobo de Aguiar, Varvara Solodovnikova, Xianglin Ruan, Lili Liang, Guolong Zhang, Hong Zhu, Yingda Xie
发表日期
2018/1/1
期刊
The Lancet infectious diseases
卷号
18
期号
1
页码范围
76-84
出版商
Elsevier
简介
Background
The Xpert MTB/RIF assay is an automated molecular test that has improved the detection of tuberculosis and rifampicin resistance, but its sensitivity is inadequate in patients with paucibacillary disease or HIV. Xpert MTB/RIF Ultra (Xpert Ultra) was developed to overcome this limitation. We compared the diagnostic performance of Xpert Ultra with that of Xpert for detection of tuberculosis and rifampicin resistance.
Methods
In this prospective, multicentre, diagnostic accuracy study, we recruited adults with pulmonary tuberculosis symptoms presenting at primary health-care centres and hospitals in eight countries (South Africa, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). Participants were allocated to the case detection group if no drugs had been taken for tuberculosis in the past 6 months or to the multidrug-resistance risk group if drugs for tuberculosis had been taken in the past 6 months …
引用总数
201720182019202020212022202320242581101271311157453